Posey Dental Office ,
-
Asthma inhalers may cost less in 2026: what the first generic Flovent HFA means
The FDA approved the first generic version of Flovent HFA in March 2026, a maintenance inhaler for people age 4 and older. That could help some families pay less for asthma control, but the actual price at the pharmacy will still depend on insurance coverage and local availability.
-
Aurora Bay Area Prices – RETICULOCYTES, AUTOMATED is $75
At Aurora Bay Area, we prioritize providing our patients with comprehensive financial information upfront. For Charge Code 10004593, regarding RETICULOCYTES, AUTOMATED, which is classified under revenue code 305 and associated with CPT code 85045, the designated fee stands at $75. Our aim through the CompareMedCosts program is to furnish you with all the details you need to make informed healthcare decisions, offering clarity and transparency around the costs associated with your care.
-
Evaluating Open Enrollment Dates for Health and Dental
In assessing open enrollment dates for health and dental plans, it is crucial to consider the diverse needs of enrollees and the logistical challenges faced by providers. Ensuring that enrollment periods are strategically timed can significantly impact participation rates and overall satisfaction. By aligning these dates with the financial and personal circumstances of potential enrollees, providers can enhance accessibility and decision-making for individuals and families. Additionally, clear communication and support throughout the enrollment process can alleviate confusion and encourage proactive engagement. Ultimately, a well-evaluated open enrollment period can lead to better coverage choices and improved health outcomes.
-
This Is Why Prescription Drugs Are So Expensive
High U.S. prescription drug costs are driven by a lack of price regulation, patent monopolies, and complex supply chain mechanics involving pharmacy benefit managers (PBMs) that incentivize high list prices. Infographics highlight that these factors, combined with extensive marketing spend over R&D, lead to soaring launch prices and increased patient cost-related non-adherence.